Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection
Status:
COMPLETED
Trial end date:
2023-08-30
Target enrollment:
Participant gender:
Summary
The incidence of fungal infection has increased dramatically over the past few decades.This is due to increase in survival rates of preterm neonates, advances in medical technology and drug therapy, broad spectrum antibiotics and parenteral nutrition . The resistance to antifungal agents has increased. This study will assess the efficacy of micafungin versus amphotericin B in neonates with positive fungal culture.